Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain

The impressive performance of Eli Lilly’s donanemab in the Phase III TRAILBLAZER-ALZ 2 study has reignited the biopharma industry’s interest in Alzheimer’s disease, triggering stock gains for several drug developers in the space.